Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.81 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940872 | 1.00 | ADORA2A (0.81) | ADORA2AADORA1ADORA2B | |
| SCHEMBL940874 | 1.00 | ADORA2A (0.81) | ADORA2AADORA1ADORA2B | |
| SCHEMBL939233 | 0.89 | ADORA2A (0.68) | ADORA2AADORA1ADORA2B | |
| SCHEMBL939231 | 0.89 | ADORA2A (0.68) | ADORA2AADORA1ADORA2B | |
| SCHEMBL939235 | 0.89 | ADORA2A (0.68) | ADORA2AADORA1ADORA2B | |
| SCHEMBL938988 | 0.88 | ADORA2A (0.70) | ADORA2AADORA1ADORA2B | |
| SCHEMBL938991 | 0.88 | ADORA2A (0.70) | ADORA2AADORA1ADORA2B | |
| SCHEMBL938990 | 0.88 | ADORA2A (0.70) | ADORA2AADORA1ADORA2B | |
| SCHEMBL939603 | 0.87 | ADORA2A (0.69) | ADORA2AADORA1ADORA2B | |
| SCHEMBL939602 | 0.87 | ADORA2A (0.69) | ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002843-A1 | METHOD OF DETECTING MYOCARDIAL DYSFUNCTION IN PATIENTS HAVING A HISTORY OF ASTHMA OR BRONCHOSPASM | BARRETT RICHARD J | 2011-01-06 | — | — | US | disclosed |
| EP-1841355-A1 | METHOD OF DETECTING MYOCARDIAL DYSFUNCTION IN PATIENTS HAVING A HISTORY OF ASTHMA OR BRONCHOSPASM | King Pharmaceuticals Research and Development Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060159621-A1 | Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006076698-A1 | METHOD OF DETECTING MYOCARDIAL DYSFUNCTION IN PATIENTS HAVING A HISTORY OF ASTHMA OR BRONCHOSPASM | KING PHARMACEUTICALS RESERCH & DEVELOPMENT, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002843-A1 | METHOD OF DETECTING MYOCARDIAL DYSFUNCTION IN PATIENTS HAVING A HISTORY OF ASTHMA OR BRONCHOSPASM | TNNI3, BDKRB2, BDKRB1 | ADORA2A 293/4885ADORA1 362/4885ADORA2B 60/4885 |
| US-20060159621-A1 | Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm | TNNI3, BDKRB2, BDKRB1 | ADORA2A 293/4885ADORA1 362/4885ADORA2B 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.